Published in J Immunol Methods on March 01, 2003
Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA. PLoS One (2014) 2.08
Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. Rheumatology (Oxford) (2011) 1.49
Evaluation of a new fluorescent-enzyme immuno-assay for diagnosis and follow-up of ANCA-associated vasculitis. J Clin Immunol (2005) 1.36
New platform technology for comprehensive serological diagnostics of autoimmune diseases. Clin Dev Immunol (2012) 1.04
Twenty-eight years with antineutrophil cytoplasmic antibodies (ANCA): how to test for ANCA - evidence-based immunology? Auto Immun Highlights (2010) 0.91
Automated interpretation of ANCA patterns - a new approach in the serology of ANCA-associated vasculitis. Arthritis Res Ther (2012) 0.87
Galactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA Associated Vasculitis. EBioMedicine (2017) 0.82
ANCA-GBM dot-blot: evaluation of an assay in the differential diagnosis of patients presenting with rapidly progressive glomerulonephritis. J Clin Immunol (2004) 0.81
Automatic reading of ANCA-slides: evaluation of the AKLIDES system. Clin Dev Immunol (2012) 0.78
Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen. Immunology (2004) 0.76
Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology. Clin Rev Allergy Immunol (2017) 0.75
Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med (2012) 6.93
Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol (2007) 6.13
Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med (2013) 5.67
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med (2013) 3.81
Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J Am Soc Nephrol (2004) 3.63
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum (2011) 3.60
Predictive performance of renal function equations in renal transplant recipients: an analysis of patient factors in bias. Am J Transplant (2005) 2.46
Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention. Am J Kidney Dis (2013) 2.41
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation (2007) 2.01
Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest (2013) 1.99
Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J Leukoc Biol (2003) 1.88
Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol (2006) 1.87
Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum (2007) 1.86
Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Renal Physiol (2006) 1.85
Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Nephrol Dial Transplant (2011) 1.82
Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum (2002) 1.79
Protective role of endothelial nitric oxide synthase. J Pathol (2003) 1.73
Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum (2004) 1.70
Early identification of risk factors for refractory secondary hyperparathyroidism in patients with long-term renal replacement therapy. Nephrol Dial Transplant (2004) 1.69
Bacterial infections in Wegener's granulomatosis: mechanisms potentially involved in autoimmune pathogenesis. Curr Opin Rheumatol (2011) 1.68
ANCA-associated vasculitides--advances in pathogenesis and treatment. Nat Rev Rheumatol (2010) 1.67
Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. Arthritis Rheum (2003) 1.65
The complement system in systemic autoimmune disease. J Autoimmun (2009) 1.64
Acute hepatitis B in a healthcare worker: a case report of genuine vaccination failure. J Hepatol (2008) 1.46
Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant (2007) 1.44
Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol (2008) 1.42
Human anti-neutrophil cytoplasm autoantibodies to proteinase 3 (PR3-ANCA) bind to neutrophils. Kidney Int (2005) 1.42
Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol (2002) 1.41
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis (2010) 1.38
Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum (2008) 1.37
High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther (2011) 1.33
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis (2011) 1.33
Vascular inflammation in cerebral small vessel disease. Neurobiol Aging (2011) 1.32
Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int (2003) 1.31
ANCA-negative pauci-immune crescentic glomerulonephritis. Nat Rev Nephrol (2009) 1.29
Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J Rheumatol (2005) 1.28
Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum (2010) 1.27
Kidney injury molecule-1 in renal disease. J Pathol (2010) 1.27
The future of damage assessment in vasculitis. J Rheumatol (2007) 1.27
Identification of autoantibody biomarkers for primary Sjögren's syndrome using protein microarrays. Proteomics (2011) 1.27
Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. Arthritis Res Ther (2011) 1.26
Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology (Oxford) (2003) 1.25
Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther (2011) 1.24
IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis. J Am Soc Nephrol (2010) 1.24
Preclinical validation of salivary biomarkers for primary Sjögren's syndrome. Arthritis Care Res (Hoboken) (2010) 1.21
Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. Clin Immunol (2011) 1.19
A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP. J Clin Gastroenterol (2009) 1.18
Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener's granulomatosis. Arthritis Rheum (2002) 1.18
Autoantibodies against protective molecules--C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci (2007) 1.15
Systems biology analysis of Sjögren's syndrome and mucosa-associated lymphoid tissue lymphoma in parotid glands. Arthritis Rheum (2009) 1.14
Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res (2001) 1.13
Health-related quality of life, employment and disability in patients with Sjogren's syndrome. Rheumatology (Oxford) (2009) 1.10
Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study. Arthritis Rheum (2005) 1.10
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol (2007) 1.09
Churg-Strauss syndrome: just one disease entity? Arthritis Rheum (2005) 1.09
Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol (2013) 1.08
Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations. Arthritis Res Ther (2012) 1.08
Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes. Ann Rheum Dis (2007) 1.07
Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transplant (2004) 1.07
Regulation of cytokine-induced HIF-1alpha expression in rheumatoid synovial fibroblasts. Ann N Y Acad Sci (2007) 1.06
Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. Arthritis Rheum (2006) 1.03
Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med (2003) 1.03
Review article: The role of CD4(+) T cells in ANCA-associated systemic vasculitis. Nephrology (Carlton) (2009) 1.03
Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis. Am J Physiol Renal Physiol (2007) 1.03
Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation (2007) 1.02
Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann Rheum Dis (2012) 1.01
Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2009) 1.01
Molecular genetic analyses of human NKG2C (KLRC2) gene deletion. Int Immunol (2004) 1.00
Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Res Ther (2008) 1.00
Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am J Physiol Renal Physiol (2007) 0.99
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. J Am Soc Nephrol (2011) 0.98
Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis (2006) 0.98
Cellular immunity in Wegener's granulomatosis: characterizing T lymphocytes. Arthritis Rheum (2009) 0.97
Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus. Arthritis Res Ther (2010) 0.97
Addition of vitamin D status to prognostic scores improves the prediction of outcome in community-acquired pneumonia. Clin Infect Dis (2012) 0.97
Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. Rheumatology (Oxford) (2010) 0.97
Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2011) 0.96
Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus. Arthritis Res Ther (2007) 0.95
Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor. BMC Musculoskelet Disord (2010) 0.94
Increased expression of Toll-like receptors by monocytes and natural killer cells in ANCA-associated vasculitis. PLoS One (2011) 0.94
Relative contribution of attention-deficit hyperactivity disorder, obsessive-compulsive disorder, and tic severity to social and behavioral problems in tic disorders. J Dev Behav Pediatr (2004) 0.94
The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev (2009) 0.94
Association of common cold with exacerbations in pediatric but not adult patients with tic disorder: a prospective longitudinal study. J Child Adolesc Psychopharmacol (2005) 0.94
The prototypic tissue pentraxin PTX3, in contrast to the short pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages. Arthritis Rheum (2004) 0.93
Biomarkers in exhaled breath condensate indicate presence and severity of cystic fibrosis in children. Pediatr Allergy Immunol (2008) 0.93
Is disturbed clearance of apoptotic keratinocytes responsible for UVB-induced inflammatory skin lesions in systemic lupus erythematosus? Arthritis Res Ther (2006) 0.93
Autoantibodies against glomerular endothelial cells in anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. Nephrology (Carlton) (2008) 0.92